City of Hope researchers found kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug, Fotivda (tivozanib), compared to an alternative approved by FDA.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
